255 related articles for article (PubMed ID: 36401046)
1. Identifying FDA-Approved Drugs that Upregulate Utrophin A as a Therapeutic Strategy for Duchenne Muscular Dystrophy.
Péladeau C; Jasmin BJ
Methods Mol Biol; 2023; 2587():495-510. PubMed ID: 36401046
[TBL] [Abstract][Full Text] [Related]
2. Correlation of Utrophin Levels with the Dystrophin Protein Complex and Muscle Fibre Regeneration in Duchenne and Becker Muscular Dystrophy Muscle Biopsies.
Janghra N; Morgan JE; Sewry CA; Wilson FX; Davies KE; Muntoni F; Tinsley J
PLoS One; 2016; 11(3):e0150818. PubMed ID: 26974331
[TBL] [Abstract][Full Text] [Related]
3. Utrophin upregulation in Duchenne muscular dystrophy.
Hirst RC; McCullagh KJ; Davies KE
Acta Myol; 2005 Dec; 24(3):209-16. PubMed ID: 16629055
[TBL] [Abstract][Full Text] [Related]
4. Utrophin upregulation for treating Duchenne or Becker muscular dystrophy: how close are we?
Miura P; Jasmin BJ
Trends Mol Med; 2006 Mar; 12(3):122-9. PubMed ID: 16443393
[TBL] [Abstract][Full Text] [Related]
5. Utrophin modulator drugs as potential therapies for Duchenne and Becker muscular dystrophies.
Soblechero-Martín P; López-Martínez A; de la Puente-Ovejero L; Vallejo-Illarramendi A; Arechavala-Gomeza V
Neuropathol Appl Neurobiol; 2021 Oct; 47(6):711-723. PubMed ID: 33999469
[TBL] [Abstract][Full Text] [Related]
6. Embryonic myosin is a regeneration marker to monitor utrophin-based therapies for DMD.
Guiraud S; Edwards B; Squire SE; Moir L; Berg A; Babbs A; Ramadan N; Wood MJ; Davies KE
Hum Mol Genet; 2019 Jan; 28(2):307-319. PubMed ID: 30304405
[TBL] [Abstract][Full Text] [Related]
7. Second-generation compound for the modulation of utrophin in the therapy of DMD.
Guiraud S; Squire SE; Edwards B; Chen H; Burns DT; Shah N; Babbs A; Davies SG; Wynne GM; Russell AJ; Elsey D; Wilson FX; Tinsley JM; Davies KE
Hum Mol Genet; 2015 Aug; 24(15):4212-24. PubMed ID: 25935002
[TBL] [Abstract][Full Text] [Related]
8. Pharmacological activation of PPARbeta/delta stimulates utrophin A expression in skeletal muscle fibers and restores sarcolemmal integrity in mature mdx mice.
Miura P; Chakkalakal JV; Boudreault L; Bélanger G; Hébert RL; Renaud JM; Jasmin BJ
Hum Mol Genet; 2009 Dec; 18(23):4640-9. PubMed ID: 19744959
[TBL] [Abstract][Full Text] [Related]
9. Unusually severe muscular dystrophy upon in-frame deletion of the dystrophin rod domain and lack of compensation by membrane-localized utrophin.
Gorokhova S; Schessl J; Zou Y; Yang ML; Heydemann PT; Sufit RL; Meilleur K; Donkervoort S; Medne L; Finkel RS; Bönnemann CG
Med; 2023 Apr; 4(4):245-251.e3. PubMed ID: 36905929
[TBL] [Abstract][Full Text] [Related]
10. Sarcolemmal nNOS anchoring reveals a qualitative difference between dystrophin and utrophin.
Li D; Bareja A; Judge L; Yue Y; Lai Y; Fairclough R; Davies KE; Chamberlain JS; Duan D
J Cell Sci; 2010 Jun; 123(Pt 12):2008-13. PubMed ID: 20483958
[TBL] [Abstract][Full Text] [Related]
11. Sarcospan integration into laminin-binding adhesion complexes that ameliorate muscular dystrophy requires utrophin and α7 integrin.
Marshall JL; Oh J; Chou E; Lee JA; Holmberg J; Burkin DJ; Crosbie-Watson RH
Hum Mol Genet; 2015 Apr; 24(7):2011-22. PubMed ID: 25504048
[TBL] [Abstract][Full Text] [Related]
12. CT-GalNAc transferase overexpression in adult mice is associated with extrasynaptic utrophin in skeletal muscle fibres.
Durko M; Allen C; Nalbantoglu J; Karpati G
J Muscle Res Cell Motil; 2010 Sep; 31(3):181-93. PubMed ID: 20706865
[TBL] [Abstract][Full Text] [Related]
13. Alternative utrophin mRNAs contribute to phenotypic differences between dystrophin-deficient mice and Duchenne muscular dystrophy.
Perkins KJ; Davies KE
FEBS Lett; 2018 Jun; 592(11):1856-1869. PubMed ID: 29772070
[TBL] [Abstract][Full Text] [Related]
14. Loss of sarcospan exacerbates pathology in mdx mice, but does not affect utrophin amelioration of disease.
Gibbs EM; McCourt JL; Shin KM; Hammond KG; Marshall JL; Crosbie RH
Hum Mol Genet; 2021 Apr; 30(3-4):149-159. PubMed ID: 33432327
[TBL] [Abstract][Full Text] [Related]
15. Duchenne muscular dystrophy drug discovery - the application of utrophin promoter activation screening.
Moorwood C; Khurana TS
Expert Opin Drug Discov; 2013 May; 8(5):569-81. PubMed ID: 23473647
[TBL] [Abstract][Full Text] [Related]
16. The potential of utrophin and dystrophin combination therapies for Duchenne muscular dystrophy.
Guiraud S; Edwards B; Babbs A; Squire SE; Berg A; Moir L; Wood MJ; Davies KE
Hum Mol Genet; 2019 Jul; 28(13):2189-2200. PubMed ID: 30990876
[TBL] [Abstract][Full Text] [Related]
17. Metabolic remodeling of dystrophic skeletal muscle reveals biological roles for dystrophin and utrophin in adaptation and plasticity.
Hardee JP; Martins KJB; Miotto PM; Ryall JG; Gehrig SM; Reljic B; Naim T; Chung JD; Trieu J; Swiderski K; Philp AM; Philp A; Watt MJ; Stroud DA; Koopman R; Steinberg GR; Lynch GS
Mol Metab; 2021 Mar; 45():101157. PubMed ID: 33359740
[TBL] [Abstract][Full Text] [Related]
18. Multiple regulatory events controlling the expression and localization of utrophin in skeletal muscle fibers: insights into a therapeutic strategy for Duchenne muscular dystrophy.
Jasmin BJ; Angus LM; Bélanger G; Chakkalakal JV; Gramolini AO; Lunde JA; Stocksley MA; Thompson J
J Physiol Paris; 2002; 96(1-2):31-42. PubMed ID: 11755781
[TBL] [Abstract][Full Text] [Related]
19. Drug discovery for Duchenne muscular dystrophy via utrophin promoter activation screening.
Moorwood C; Lozynska O; Suri N; Napper AD; Diamond SL; Khurana TS
PLoS One; 2011; 6(10):e26169. PubMed ID: 22028826
[TBL] [Abstract][Full Text] [Related]
20. Identification of FHL1 as a therapeutic target for Duchenne muscular dystrophy.
D'Arcy CE; Feeney SJ; McLean CA; Gehrig SM; Lynch GS; Smith JE; Cowling BS; Mitchell CA; McGrath MJ
Hum Mol Genet; 2014 Feb; 23(3):618-36. PubMed ID: 24087791
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
